Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 2/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787924 | 1.00 | F7 (0.41) | F7ALDH1A1GAAKDM4EMAPT | |
| SCHEMBL6797477 | 0.86 | F7 (0.43) | F7ALDH1A1GAAF3SYK | |
| SCHEMBL6797466 | 0.86 | F7 (0.43) | F7ALDH1A1GAAF3SYK | |
| SCHEMBL8360867 | 0.85 | F7 (0.42) | F7ALDH1A1GAAMAPTF3 | |
| SCHEMBL6791726 | 0.84 | F7 (0.48) | F7ALDH1A1F3SYK | |
| SCHEMBL6791732 | 0.84 | F7 (0.48) | F7ALDH1A1F3SYK | |
| SCHEMBL6791187 | 0.83 | F7 (0.41) | F7ALDH1A1GAAMAPTF3 | |
| SCHEMBL6791181 | 0.83 | F7 (0.41) | F7ALDH1A1GAAMAPTF3 | |
| SCHEMBL8360874 | 0.81 | F7 (0.42) | F7GAAKDM4EMAPTF3 | |
| SCHEMBL6792675 | 0.81 | F7 (0.39) | F7ALDH1A1GAAF3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, TFPI2 | F7 20/4885ALDH1A1 1468/4885GAA 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.